BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) Director Orbimed Advisors Llc acquired 625,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
BlossomHill Therapeutics Price Performance
BlossomHill Therapeutics stock opened at $16.18 on Friday. BlossomHill Therapeutics, Inc. has a 1 year low of $15.25 and a 1 year high of $17.25.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a report on Saturday.
About BlossomHill Therapeutics
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.
Read More
- Five stocks we like better than BlossomHill Therapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
